Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene ...

CAR-T cell therapy has revolutionized immunotherapy but its allogeneic ... the use of a device like the CliniMACS or its automated counterpart, the Prodigy (Miltenyi Biotec, Bergisch-Gladbach, Germany ...

The therapy ... cells genetically modified to express anti-CD20 and CD19 immunoreceptors. It is being developed based on tandem CART technology. It was under development for chronic lymphocytic ...

Introduction: Allogeneic chimeric antigen receptor T (CAR-T) therapy ... a 1:1 bead-to-cell ratio in CTS™ OpTmizer™ T Cell Expansion SFM (Gibco), supplemented with 5% human platelet lysate, 5 ng/mL IL ...

The Canadian-Led Immunotherapies in Cancer (CLIC) programme has built a network to support the production of CAR T-cell products fully made in Canada ... The CliniMACS Prodigy (Miltenyi Biotec, ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

“Some gene therapy products are also in the clinical trial phase,” IRNA quoted the FDA director, Mehdi Pirsalehi, as saying. Referring to the country’s scientific progress in the pharmaceutical sector ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...